Skip To Main Content
Tawbi HA on Muck Rack

Tawbi HA

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tawbi

Contact Tawbi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition

|
By Kreidieh FY, Tawbi HA, Firas Y Kreidieh, Hussein Tawbi
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (655) Issue with article?

Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development

|
By Tawbi HA, Kandalaft LE, Kreidieh FY
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared Issue with article?

Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!

|
By Keung EZ, Tawbi HA
| ncbi.nlm.nih.gov
Synovial sarcoma (SS) is an aggressive malignancy that typically affects adolescents and young adults and is associated with poor prognosis. Although SS has failed to respond to immune checkpoint blockade, other strategies designed to generate an immune response, including adoptive cell therapies targeting the cancer testis antigen NY-ESO-1, have shown encouraging results.
Open in Who Shared Issue with article?
See all 4 articles